IUL Stock Chart & Stats
€9.60
-€0.40(-4.00%)
At close: 4:00 PM EDT
€9.60
-€0.40(-4.00%)
Day’s Range― - ―
52-Week Range€3.88 - €10.20
Previous CloseN/A
Volume0.00
Average Volume (3M)24.00
Market Cap
€87.94M
Enterprise Value€90.87M
Total Cash (Recent Filing)€6.81M
Total Debt (Recent Filing)€12.78M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding9,046,799
10 Day Avg. Volume73
30 Day Avg. Volume24
Financial Highlights & Ratios
PEG Ratio0.95
Price to Book (P/B)2.05
Price to Sales (P/S)2.01
P/FCF Ratio45.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Cash GenerationSustained positive operating and free cash flow provides durable internal funding for capex, working capital and capacity expansion without immediate reliance on external financing. If maintained, it underpins reinvestment in production and commercialization over the next 2–6 months.
Lower Leverage / Stronger Balance SheetMaterial debt reduction and sizable equity provide financial flexibility to fund the planned capacity program and absorb shocks. A lower leverage profile reduces interest burden and improves the company's ability to execute multi-month manufacturing projects and commercial expansion.
Market Share And Product LeadershipClear share gains and strong demand for flagship biologics indicate durable competitive positioning in a growing category. Premium product adoption and rising unit output create a structural advantage to capture ongoing category expansion and convert market leadership into sustained revenue growth.
Bears Say
International Revenue WeaknessA sharp international decline limits access to an addressable market management estimates is much larger than U.S. Underperformance abroad suggests commercialization, distribution or regulatory execution gaps that could impede durable multi‑region growth absent targeted investment and management focus.
Manufacturing / Capacity Execution RiskExecution risks in production are structural: contamination and large-scale plant repurposing can cause prolonged outages, variability in availability and lost sales. The 12‑month expansion timeline and required process controls mean supply reliability is a material operational risk for months ahead.
Inconsistent Bottom‑Line ProfitabilityWhile operating results recovered, persistent small net losses limit the company’s ability to reliably compound shareholder value or return capital. Durably positive net income is needed to convert improved cash flow and margins into sustainable profitability and reduce earnings volatility.
Immucell News
IUL FAQ
What was Immucell Corp.’s price range in the past 12 months?
Immucell Corp. lowest stock price was €3.88 and its highest was €10.20 in the past 12 months.
What is Immucell Corp.’s market cap?
Immucell Corp.’s market cap is €87.94M.
When is Immucell Corp.’s upcoming earnings report date?
Immucell Corp.’s upcoming earnings report date is Aug 13, 2026 which is in 6 days.
How were Immucell Corp.’s earnings last quarter?
Immucell Corp. released its earnings results on May 14, 2026. The company reported €0.189 earnings per share for the quarter, beating the consensus estimate of N/A by €0.189.
Is Immucell Corp. overvalued?
According to Wall Street analysts Immucell Corp.’s price is currently Overvalued.
Does Immucell Corp. pay dividends?
Immucell Corp. does not currently pay dividends.
What is Immucell Corp.’s EPS estimate?
Immucell Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Immucell Corp. have?
Immucell Corp. has 9,046,799 shares outstanding.
What happened to Immucell Corp.’s price movement after its last earnings report?
Immucell Corp. reported an EPS of €0.189 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.797%.
Which hedge fund is a major shareholder of Immucell Corp.?
Currently, no hedge funds are holding shares in DE:IUL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immucell Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
27.91%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.32%
Trailing 12-Months
Company Description
Immucell Corp.
ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.
IUL Company Deck
IUL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized a number of meaningful operational and commercial positives including a record $10.4M revenue quarter, strong domestic growth, improved gross margins and net income, significant manufacturing yield gains and market share expansion led by Tri-Shield. Management also highlighted disciplined investments in commercial coverage, international planning, and a $2.0M settlement earmarked for capacity expansion. Key risks remain around international sales weakness, higher operating expenses, and executional manufacturing/capacity challenges (contamination risk and the need for a major processing-plant expansion). Overall, the positives—record revenue, margin and income improvements, visible market-share gains, and capital to invest in capacity—appear to materially outweigh the lowlights in the near term.View all DE:IUL earnings summariesTechnical Analysis
Inovio Pharmaceuticals
―
Arcturus Therapeutics
―
XBiotech
―
PDS Biotechnology
―
Rani Therapeutics Holdings
―